I-Mab (NASDAQ:NBP) Receives Buy Rating from HC Wainwright

Key Points

• HC Wainwright reiterated a "Buy" on I-Mab with a $9.00 price target, implying about a 262.9% upside from the current share price.
• Analyst sentiment is mixed and the consensus is a "Hold": one analyst has a Buy, one a Sell, Weiss Ratings started coverage with a Sell (D-) and Wall Street Zen recently downgraded the stock to Hold.
• I-Mab is trading around $2.48 with a market cap of about $286 million, reported a quarterly EPS of negative $0.30, has a 52-week range of $0.62–$6.79, and institutional investors own roughly 38% of the shares.

I-Mab (NASDAQ:NBP - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $9.00 price target on the stock. HC Wainwright's target price points to a potential upside of 262.90% from the company's current price.

Several other research analysts also recently weighed in on NBP. Weiss Ratings assumed coverage on I-Mab in a research note on Thursday, February 5th. They issued a "sell (d-)" rating on the stock. Wall Street Zen downgraded I-Mab from a "buy" rating to a "hold" rating in a report on Saturday, March 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, I-Mab currently has a consensus rating of "Hold" and a consensus target price of $9.00.

I-Mab Stock Performance

NBP opened at $2.48 on Wednesday. The firm has a market capitalization of $285.92 million, a price-to-earnings ratio of -6.89 and a beta of 1.74. I-Mab has a 52 week low of $0.62 and a 52 week high of $6.79. The stock's 50 day moving average price is $3.01.

I-Mab (NASDAQ:NBP - Get Free Report) last released its quarterly earnings results on Tuesday, April 7th. The company reported ($0.30) EPS for the quarter.

Hedge Funds Weigh In On I-Mab

A hedge fund recently bought a new stake in I-Mab stock. Brooklyn Investment Group bought a new position in shares of I-Mab (NASDAQ:NBP - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 12,715 shares of the company's stock, valued at approximately $51,000. Hedge funds and other institutional investors own 38.38% of the company's stock.

About I-Mab

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.